YERVOY 5 mg/ml concentrate for solution for infusion clinical trials
15 indexed studies · 0 currently recruiting
- Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase I Study of INCB099280 in Combination With Ipilimumab in Participants With Selected Solid Tumors
This early-stage study is testing a new drug, INCB099280, combined with an existing cancer treatment, YERVOY, for solid tumours. Researchers want to see if this combination causes any serious side effects and how much of the new drug stays in the body. It's a first step to understand safety.
For: Solid tumorSweden · Norway · Slovakia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
This study is looking at new ways to treat bladder cancer that has spread or can't be removed with surgery. It compares a new combination of medicines with standard chemotherapy to see which works best at helping people live longer. Participants will be randomly assigned to different treatment groups.
For: Untreated Unresectable or Metastatic Urothelial CancerGermany · Greece · Denmark - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
An Open-Label, Multicentre Phase 1b/2a Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32b), in Combination with Ipilimumab and Pembrolizumab in Participants with Unresectable or Metastatic Melanoma
This study is testing new combinations of medicines for advanced melanoma, a type of skin cancer that has spread or can't be removed by surgery. It looks at how safe the medicines are and how well they shrink tumours.
For: Unresectable or Metastatic MelanomaGermany · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
IFCT-1701 DICIPLE A randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in treatment-naive patients with stage IV Non-Small Cell Lung Cancer (NSCLC) after Nivolumab-Ipilimumab induction treatment
This study looks at a new way to treat advanced lung cancer. It compares continuing a combination of two immunotherapy drugs (Nivolumab and Ipilimumab) after initial treatment with simply watching to see what happens. The goal is to find out which approach works better at keeping the cancer from growing.
For: Non small cell lung cancerFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase II non randomized clinical trial of NIVOLUMAB/IPILIMUMAB maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer (SOGUG-VEXILLUM)
This study is looking at two medicines, nivolumab and ipilimumab, for people with advanced bladder cancer that can’t be removed by surgery. It wants to see if these medicines can help keep the cancer from growing after initial chemotherapy.
For: Unresectable locally advanced or metastatic urothelial cancerSpain - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase 2 INSPIRE trial: Ipilimumab with Nivolumab in molecular-selected patients with castration-resistant prostate cancer
This study is testing two new medicines, YERVOY and OPDIVO, for men with prostate cancer that has spread and is no longer responding to standard hormone therapy. We want to see how well they control the cancer and if they cause any side effects.
For: castration-resistant prostate cancerNetherlands - Ongoing, recruitingTherapeutic confirmatory (Phase III)
CA209-8HW A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
This study looks at new drug combinations for advanced bowel cancer that has specific genetic changes (MSI-H or dMMR). It compares them to standard chemotherapy to see which is better at stopping the cancer from growing.
For: Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient Metastatic Colorectal Cancer (dMMR)Austria · Italy · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti- PD-1 Antibody) and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
This study is testing new combinations of anti-cancer medicines for people with advanced non-small cell lung cancer. It aims to see if these new approaches can help people live longer and improve their quality of life, compared to standard treatments.
For: Non-small Cell Lung CancerFrance · Poland · Ireland - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A PHASE 1/2 STUDY OF ONCOBAX®-AK ADMINISTERED IN COMBINATION WITH IMMUNOTHERAPY TO PATIENTS WITH ADVANCED SOLID TUMORS
This study is testing a new treatment called Oncobax®-AK, given alongside established immunotherapy drugs, for people with advanced lung or kidney cancer. It's looking for the safest dose and early signs of how well it works. This is an early-stage trial, focusing on safety.
For: Non-Small Cell Lung Cancer (NSCLC) · Renal Cell Carcinoma (RCC)Belgium · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A phase II trial of an individualized treatment strategy for patients with metastatic non-clear cell renal carcinoma
This study is testing different medicines for people with advanced kidney cancer (non-clear cell renal carcinoma) that has spread. It's looking for personalised treatments to see which ones shrink the cancer and how long they keep it under control. The goal is to find better ways to treat this type of cancer.
For: Metastatic non-clear cell renal cell carcinomaDenmark - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma
This study looks at a new treatment called IMCgp100 for advanced eye melanoma that has not been treated before. It compares this new drug to standard treatments to see which works best and is safest for patients.
For: Previously untreated advanced uveal melanoma (UM)Spain · Italy · Belgium - AuthorisedTherapeutic exploratory (Phase II)
A phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with melanoma brain metastases
This study looks at combining two existing cancer drugs, YERVOY and OPDIVO, with or without special radiation therapy for people with melanoma that has spread to the brain. It aims to see how well this combination works.
For: melanoma brain metastasesItaly - AuthorisedTherapeutic exploratory (Phase II)
Analysis of the efficacy and safety of two combination treatment regimens of nivolumab and ipilimumab in patients with dMMR and / or MSI metastatic colorectal cancer: A GERCOR open-label, randomized, non-comparative, two-stage phase II trial (NIPISAFE)
This study looks at two types of drug combinations (nivolumab and ipilimumab) for people with advanced bowel cancer that has specific genetic changes (dMMR and/or MSI). It's a Phase II study checking how safe these treatments are and how well they stop the cancer from growing.
For: Patients with DMMR and/or MSI metastatic colorectal cancerFrance - AuthorisedPhase II and Phase III (Integrated)
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma
This study looks at new ways to treat a type of skin cancer in the eye that has spread (metastatic uveal melanoma). It compares two drug combinations, RP2 with Nivolumab, against Ipilimumab with Nivolumab, to see which is safer and more effective.
For: metastatic uveal melanomaGermany · Italy · France - AuthorisedPhase I and Phase II (Integrated)- Other
Changes in the tumour microenvironment after intravenous or intradermal administration of anti-CTLA-4 in combination with anti-PD1 treatment in patients with melanoma
This study looks at how combining two anti-cancer drugs, YERVOY and an anti-PD1 treatment, affects the body's immune system in people with advanced melanoma. Researchers want to see if giving YERVOY directly into the skin works differently from giving it into a vein.
For: unresectable stage III – IV melanomaNetherlands